The revenue growth includes contributions from Core Diagnostics, Scientific Pathology (Scientific), Agra and Dr. Ahuja’s Pathology & Imaging Center (DAPIC), Dehradun.

The TruHealth Wellness and Specialty segments posted YoY growth of about 25% and 36%, respectively, in Q2FY26.

B2C revenues registered a YoY growth of around 16%, while B2B revenues grew approximately 34% driven by higher contribution of B2B business in core diagnostics.

During the quarter, the company acquired Dr. RS Patil’s Ambika Pathology Laboratory, Kolhapur (Ambika Pathology), effective September 18, 2025. This acquisition strengthens the company’s leadership position in the Kolhapur region and is strategically aimed at establishing a mini reference laboratory to serve the surrounding 4–5 districts in the Western Maharashtra belt aiming to boost productivity, increase throughput, and reduce turnaround time (TAT).

On a consolidated basis, the company is debt free and has net cash surplus of around Rs 55 crore.

On standalone basis, the company’s revenue grew by approximately 12% YoY, driven by an increase in patient and test volumes, a favorable shift in product mix, and improved realizations.

EBITDA margins for the current quarter saw a QoQ improvement, reflecting resilient business operations and strong operating leverage inherent in the business model. Margins also showed a positive year-on-year trend.

Metropolis Healthcare provides diagnostic services to patients, healthcare providers, and corporates across India and Africa. It offers a comprehensive range of more than 4,100 tests and profiles, including advanced tests for diagnosing cancer, neurological disorders, infectious diseases, and various genetic abnormalities.

The company’s consolidated net profit jumped 18.7% to Rs 45.06 crore on 23.2% increase in net sales to Rs 386.06 crore in Q1 FY26 over Q1 FY25.